All enrolled sufferers who acquired no less than just one dose of zosuquidar or placebo during induction ended up monitored to the event of adverse occasions (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been associated with the duration of prolonged and significant myelosuppression https://chanceisudu.shoutmyblog.com/27713970/details-fiction-and-ponsegromab